SCHEMBL22553386

SCHEMBL22553386

O=c1ccc(Br)cn1C1CS(=O)(=O)C1

nearest known ligand 0.41

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
MAPT P10636 1/20 0.32
GAA P10253 1/20 0.31
RAB9A P51151 1/20 0.31
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL589967 0.81 BMPR1B (0.35) MEN1KMT2AKDM4EALDH1A1
SCHEMBL7267066 0.59
SCHEMBL2114660 0.59
SCHEMBL506014 0.56 MEN1 (0.33) MEN1KMT2AALDH1A1
SCHEMBL10178071 0.56 BMPR1B (0.40) MEN1KMT2AMAPTKDM4EALDH1A1
SCHEMBL31313713 0.55 KDM4E (0.35) MEN1KMT2AKDM4E
SCHEMBL506044 0.55 ADORA2A (0.38) ADORA2AADORA1ALDH1A1
SCHEMBL14407062 0.55 KDM4E (0.38) MAPTKDM4EALDH1A1
SCHEMBL12197718 0.55 L3MBTL1 (0.38) MEN1KMT2AMAPTRAB9AKDM4E
SCHEMBL3860760 0.54 KMT2A (0.40) MEN1KMT2AMAPTRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11629147-B2 Triazolo-pyrimidine compounds and uses thereof DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-04-18 US disclosed
US-20210009600-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2021-01-14 US disclosed
US-10858365-B2 Triazolo-pyrimidine compounds and uses thereof DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2020-12-08 US disclosed
US-20200331918-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2020-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210009600-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF ADORA2A, ADORA3, ADORA2B MEN1 3612/4885KMT2A 3487/4885ADORA2A 1/4885
US-11629147-B2 Triazolo-pyrimidine compounds and uses thereof ADORA2A, ADORA3, ADORA2B MEN1 3612/4885KMT2A 3487/4885ADORA2A 1/4885
US-10858365-B2 Triazolo-pyrimidine compounds and uses thereof ADORA2A, ADORA3, ADORA2B MEN1 3612/4885KMT2A 3487/4885ADORA2A 1/4885
US-20200331918-A1 TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF ADORA2A, ADORA3, ADORA2B MEN1 3612/4885KMT2A 3487/4885ADORA2A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.